%2520(1).png%3Fv%3D63925259635&w=96&q=100){kind=small}
2022 was landmark year for Accrufer® and Viatris agreement sets us up for a strong 2023
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask Shield Therapeutics a question about this update.